Adial Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Adial Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Adial Pharmaceuticals, Inc..
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc.
3.91
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $1.9M | 84.23% | new |
| Jane Street | $82,225 | 3.72% | new |
| Citadel | $75,640 | 3.42% | new |
| Intl Fcstone | $50,000 | 2.26% | new |
| UBS | $49,017 | 2.22% | +3432.66% |
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $1.9M | 84.23% | new |
| Jane Street | $82,225 | 3.72% | new |
| Citadel | $75,640 | 3.42% | new |
| Intl Fcstone | $50,000 | 2.26% | new |
| UBS | $49,017 | 2.22% | +3432.66% |
+32.24%
shares held · 10 largest managers
Expected move
No implied move.
Bull2
Bear1